Mist from stem cell byproducts for autoimmune lung disease
Part of Lungs & breathing clinical trials.
This study tests a new type of treatment using a mist (nebulized) made from stem cell byproducts to see if it can safely help people with a rare autoimmune lung disease. It is for patients with anti-MDA5 positive dermatomyositis who have a fast-progressing lung condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a specific type of autoimmune disease called anti-MDA5 positive dermatomyositis, which affects your skin and muscles.
- You have a fast-worsening lung condition linked to your disease, known as rapidly progressive interstitial lung disease (RP-ILD).
- You are not pregnant or breastfeeding, and if you are a man, you agree to use birth control during the study.
- You do not have a severe lung infection, collapsed lung, or large fluid buildup around your lungs right now.
- You are not on a breathing tube ventilator or on advanced life support machines (like ECMO or dialysis for blood filtering).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an inhaled mist made from tiny particles that may reduce allergy and asthma symptoms. It might help people whose current allergy medicines are not working well enough.
This trial looks at how the immune system and tiny organisms in the lungs may affect a rare condition called anti-MDA5 positive dermatomyositis, which can cause serious lung disease. It may help doctors understand why some patients get worse quickly and how to better treat them.
This trial tests a new stem cell treatment made from umbilical cord cells for people with ARDS, a serious lung condition. The treatment may help reduce inflammation and improve lung function.
This study tests a new treatment that is breathed in as a mist (nebulized) and uses tiny particles from cells (called extracellular vesicles) to help calm the immune system. It is for people with IgG4-related disease or systemic sclerosis that have lung problems, and may help reduce inflammation and improve breathing.
This trial tests whether combining two drugs, rituximab and mycophenolate mofetil, is safe and works better than standard care for lung scarring caused by scleroderma. It may be an option if your lung disease is severe or getting worse.
This trial tests a new treatment using stem cells from umbilical cords to help people with scleroderma-related lung disease. It aims to see if the treatment can slow down or improve lung scarring and breathing problems.
Hear when a new Anti-MDA5 Positive Dermatomyositis-Associated RP-ILD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.